Skip to main content

Table 1 Clinical characteristics of the study population (N = 78) in this study

From: Association of exacerbation phenotype with the sputum microbiome in chronic obstructive pulmonary disease patients during the clinically stable state

Characteristics

All

Low risk exacerbator (LRE)

High risk exacerbator (HRE)

PFT I

PFT II

Number of patients

78

60

18

43

35

Age (years)

 Range

40–93

40–91

52–93

40–90

52–93

 Mean ± s.e.m

74.17 ± 1.446

73.63 ± 1.673

75.94 ± 2.889

72.37 ± 2.020

76.37 ± 2.025

Gender

 Male

68 (87.2%)

50 (83.3%)

18 (100%)

36 (83.7%)

32 (91.4%)

 Female

10 (12.8%)

10 (16.7%)

0 (0%)

7 (16.3%)

3 (8.6%)

FEV1 (% predicted)

 Range

24.6–97.9

30.5–97.9

24.6–73.8

50.0–97.9

24.6–49.6

 Mean ± s.e.m

53.24 ± 1.682

55.73 ± 1.902

44.95 ± 2.901

63.62 ± 1.702

40.49 ± 1.097

FEV1/FVC

 Range

37.31–69.54

45.33–69.54

37.31–66.86

52.30–69.54

37.31–69.18

 Mean ± s.e.m

59.59 ± 0.767

60.98 ± 0.783

54.95 ± 1.673

62.45 ± 0.738

56.07 ± 1.218

Current smoking

 No

17 (21.8%)

13 (21.7%)

4 (22.2%)

11 (25.6%)

6 (17.1%)

 Yes

61 (78.2%)

47 (78.3%)

14 (77.8%)

32 (74.4%)

29 (82.9%)

Medication

 LAB

31 (39.7%)

28 (46.7%)

3 (16.7%)

28 (65.1%)

3 (8.6%)

 LABA + ICS

45 (57.7%)

30 (50.0%)

15 (83.3%)

13 (30.2%)

32 (91.4%)

 No

2 (2.6%)

2 (3.3%)

0 (0%)

2 (4.7%)

0 (0%)

  1. LRE low risk exacerbator, HRE high risk exacerbator, PFT pulmonary function test, PFT I FEV1 ≥ 50, PFT II FEV1 < 50, FEV1 forced expiratory volume in the first second, FVC forced vital capacity, LAB long-acting bronchodilator, LABA long-acting β2 agonists, ICS inhaled corticosteroid